Louis Moore Bacon's AGIO Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 55.0K shares of Agios Pharmaceuticals, Inc. (AGIO) worth $2.21 M, representing 0.03% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 6 quarters.
Based on 13F filings, Louis Moore Bacon has maintained this position in AGIO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2024, adding 40.0K shares. Largest reduction occurred in Q4 2024, reducing 40.0K shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Agios Pharmaceuticals (AGIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Agios Pharmaceuticals (AGIO) Trades by Louis Moore Bacon
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2024 | +60,000 | New Buy | 60,000 | $43.12 |
| Q3 2024 | +40,000 | Add 66.67% | 100,000 | $44.43 |
| Q4 2024 | -40,000 | Reduce 40.00% | 60,000 | $32.86 |
| Q2 2025 | +20,000 | Add 33.33% | 80,000 | $33.26 |
| Q3 2025 | -25,000 | Reduce 31.25% | 55,000 | $40.14 |
Louis Moore Bacon's Agios Pharmaceuticals Investment FAQs
Louis Moore Bacon first purchased Agios Pharmaceuticals, Inc. (AGIO) in Q2 2024, acquiring 60,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Agios Pharmaceuticals, Inc. (AGIO) for 6 quarters since Q2 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon's largest addition to Agios Pharmaceuticals, Inc. (AGIO) was in Q2 2024, adding 60,000 shares worth $2.59 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 55,000 shares of Agios Pharmaceuticals, Inc. (AGIO), valued at approximately $2.21 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Agios Pharmaceuticals, Inc. (AGIO) represents approximately 0.03% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon's peak holding in Agios Pharmaceuticals, Inc. (AGIO) was 100,000 shares, as reported at the end of Q3 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.